𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neuroendocrine differentiation and hormone-refractory prostate cancer

✍ Scribed by Abrahamsson, Per-Anders


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
507 KB
Volume
29
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

✦ Synopsis


There is an intriguing link between differentiation of neuroendocrine cells and tumor progression in prostate cancer. Neuroendocrine differentiation appears to be associated with the androgen-independent state, for which there is currently no successful therapy. However, the role of the neuroendocrine cells is complex, both in the normal prostate and in the pathway toward malignancy. One important area of research is to investigate the hormones expressed by prostatic neuroendocrine cells and, in particular, to elucidate their sigruficance to androgen independence. It is hoped that an understanding of the specific roles of hormones such as somatostatin, bombesin, and serotonin in prostate cancer may lead to improved therapeutic approaches.


πŸ“œ SIMILAR VOLUMES


Steroid hormones, polypeptide growth fac
✍ Andreas I. Evangelou; Scott F. Winter; Wendy J. Huss; Robert A. Bok; Norman M. G πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 585 KB

## Abstract The growth, development, and differentiation of the prostate gland is largely dependent on the action of androgens and peptide growth factors that act differentially at the level of the mesenchymal and epithelial compartments. It is our premise that to understand the emergence of metast

Regressive changes and neuroendocrine di
✍ Ahlgren, G.; Pedersen, K.; Lundberg, S.; Aus, G.; Hugosson, J.; Abrahamsson, P.- πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 260 KB πŸ‘ 1 views

## BACKGROUND. We studied the extent of neuroendocrine (NE) tumor cell differentiation and its relation to regressive changes in prostate cancer after 3-month hormonal treatment. METHODS. Radical prostatectomy specimens from 103 patients, randomized to 3-month neoadjuvant LH-RH-analogue treatment (